Gilead CEO: We still intend to invest in M&A and our pipeline

Gilead CEO John Milligan speaks to CNBC's Meg Tirrell at the J.P. Morgan Health Care Conference about the company's M&A outlook, drug pricing and their work on cancer and Hepatitis C treatments.

from Mergers and Acquisitions http://ift.tt/2FkD20k